ProCE Banner Activity

Key HIV Studies From CROI 2024 Influencing Clinical Practice

Conference Coverage
Podcast Episodes

Joseph J. Eron, Jr., MD, and Monica Gandhi, MD, MPH, discuss the most clinically relevant new data presented at CROI 2024, including long-acting ART, comorbidities and coinfections, and what’s on the horizon in HIV treatment.

Released: March 29, 2024

Expiration: March 28, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported through independent educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Disclosure

Primary Author

Joseph J. Eron, Jr., MD

Herman and Louise Smith Distinguished Professor of Medicine
Chief, Division of Infectious Disease
Director, Clinical Core, UNC Center for AIDS Research
Adjunct Professor of Epidemiology, Gillings School of Global Public Health
University of North Carolina at Chapel Hill School of Medicine
Chapel Hill, North Carolina

Joseph J. Eron Jr., MD: consultant/advisor/speaker: AbbVie, Gilead, Merck, ViiV; researcher: Gilead, ViiV.

Monica Gandhi, MD, MPH

Director, UCSF-Bay Area Center for AIDS Research (CFAR)
Professor of Medicine and Associate Chief, Division of HIV, Infectious Diseases, and Global Medicine
Medical Director, “Ward 86” HIV Clinic, San Francisco General Hospital
University of California, San Francisco (UCSF)
San Francisco, California

Monica Gandhi, MD, MPH, has no relevant financial relationships to disclose.